Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Autolus Therapeutics plc (Nasdaq: AUTL), an innovative biopharmaceutical company based in London and Gaithersburg, Maryland, is set to participate in the Jefferies Global Healthcare Conference taking place in London. The presentation will feature Chief Executive Officer Dr. Christian Itin, who will engage in a Fireside Chat scheduled for Tuesday, November 18, 2025, at 7:30 AM EST / 12:30 PM GMT. Interested investors and stakeholders can access a live webcast of the event through the “Events” section under “Investor Relations & Media” on Autolus's website, www.autolus.com. A replay of the webcast will be available for 90 days after the presentation.

Autolus Therapeutics specializes in developing next-generation programmed T cell therapies aimed at combating cancer and autoimmune diseases. With its proprietary modular T cell programming technologies, the company is able to engineer T cell therapies that are specifically designed to improve target recognition, disrupt the defense mechanisms of harmful cells, and effectively eliminate these cells from the body.

Currently, Autolus offers a marketed therapy known as AUCATZYL®, and its developmental pipeline includes a variety of candidates targeting hematological malignancies and solid tumors, as well as treatments for autoimmune conditions. This focus on precision engineering positions Autolus at the forefront of advancements in immunotherapy, offering hope for novel treatment options where traditional therapies may fall short.

For additional information about Autolus Therapeutics, their current projects, and upcoming events, interested parties can visit their official website. For inquiries, Amanda Cray is available to provide assistance via phone or email.

As Autolus Therapeutics (Nasdaq: AUTL) gears up for its participation in the Jefferies Global Healthcare Conference in London, stakeholders should watch closely for key insights emerging from this high-profile event. The conference serves as a vital platform for companies like Autolus, which is at the forefront of developing next-generation programmed T cell therapies. Autolus's innovative approach to engineering T cell therapies holds promise for revolutionizing treatments for cancer and autoimmune diseases.

Investors should pay special attention to remarks from CEO Dr. Christian Itin during the fireside chat on November 18. This session will likely provide critical updates on the company’s marketed therapy, AUCATZYL®, and insights into the progress of its pipeline candidates. With a focus on targeting hematological malignancies and solid tumors, Autolus’s strategic positioning within the biopharmaceutical landscape appears to be strengthening, especially as the demand for advanced cancer therapies continues to rise.

Given its early commercial stage and the promising nature of its proprietary technologies, Autolus has the potential for significant growth. However, investors should remain mindful of the inherent risks associated with biotechnology investments, including the volatility surrounding clinical trial outcomes and market acceptance of new therapies.

Market analysts recommend a cautious but optimistic stance on Autolus shares, particularly as the company is poised to showcase advancements in its technology at the conference. This event could catalyze investor interest, particularly if the company can effectively communicate its growth strategy and clinical progress. With Autolus dedicated to improving patient outcomes through innovative treatments, there lies potential for appreciation in shareholder value as the company continues to develop and commercialize its therapies.